Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.58 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2194424 | 0.99 | MAOB (0.59) | MAOBHTR6GBA1NR4A2MAOA | |
| SCHEMBL12420658 | 0.88 | MAOB (0.56) | MAOBHTR6NR4A2KCNH2PARP10 | |
| SCHEMBL3966432 | 0.83 | GBA1 (0.62) | HTR6GBA1 | |
| SCHEMBL1532769 | 0.83 | MAOB (0.59) | MAOBHTR6NR4A2KCNH2PARP10 | |
| Hydrochloric Acid SCHEMBL2192010 | 0.82 | MAOB (0.60) | MAOBHTR6NR4A2KCNH2PARP10 | |
| Hydrochloric Acid SCHEMBL4777854 | 0.82 | GBA1 (0.61) | HTR6GBA1 | |
| Hydrochloric Acid SCHEMBL30522822 | 0.82 | GBA1 (0.61) | HTR6GBA1 | |
| SCHEMBL6929938 | 0.82 | SLC6A4 (0.52) | HTR6GBA1KCNH2 | |
| SCHEMBL12735859 | 0.81 | MAOB (0.50) | MAOBHTR6NR4A2MAOAKCNH2 | |
| SCHEMBL1532864 | 0.80 | MAOB (0.52) | MAOBHTR6NR4A2MAOAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MAOB 222/4885HTR6 3435/4885GBA1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.